Auranofin-loaded nanoparticles as a new therapeutic tool to fight streptococcal infections

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Díez Martínez, Roberto ^a,b,e   García Fernández, Esther ^a,b   Manzano, Miguel ^c,d   Martínez, Ángel ^c,d   Domenech, Mirian ^a,b   Vallet Regí, María ^c,d   García, Pedro ^a,b  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^e Zebrafish Lab   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTIRHEUMATIC AGENT; AURANOFIN; DRUG CARRIER; LACTIC ACID; NANOPARTICLE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANIMAL; BIOFILM; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; DRUG RELEASE; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MICROBIOLOGY; PARTICLE SIZE; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE; ULTRASTRUCTURE; ZEBRA FISH;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIRHEUMATIC AGENTS; AURANOFIN; BIOFILMS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; DRUG LIBERATION; LACTIC ACID; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; NANOPARTICLES; PARTICLE SIZE; POLYGLYCOLIC ACID; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE; ZEBRAFISH;

EID: 84955067624     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep19525     Document Type: Article

References (53)

1. WHO. Antimicrobial resistance, global report on surveillance, (2014) (last accessed 16/11/2015
2. O?Brien, K. L., et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374, 893-902 (2009
3. Said, M. A., et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-Analysis of diagnostic techniques. PloS one 8, e60273 (2013
4. Klugman, K. P. Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections. Eur. Respir. J. 20 (Suppl. 36), 3s-8s (2002
5. Fuller, J. D., & Low, D. E. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin. Infect. Dis. 41, 118-121 (2005
6. Jernigan, D. B., Cetron, M. S., & Breiman, R. F. Minimizing the impact of drug-resistant streptococcus pneumoniae (DRSP): A strategy from the DRSP working group. JAMA: the journal of the American Medical Association 275, 206-209 (1996
7. Ogawa, T., et al. Biofilm formation or internalization into epithelial cells enable Streptococcus pyogenes to evade antibiotic eradication in patients with pharyngitis. Microb. Pathog. 51, 58-68 (2011
8. McCarthy, M. CDC calls for urgent action to combat rise of drug resistant pathogens. British Med. J. 347, f5649 (2013
9. Chong, C. R., & Sullivan, D. J., Jr. New uses for old drugs. Nature 448, 645-646 (2007
10. Aronson, J. K. Old drugs -new uses. Br. J. Clin. Pharmacol. 64, 563-565 (2007
11. Shaw, C. F. Gold-based therapeutic agents. Chem. Rev. 99, 2589-2600 (1999
12. Madeira, J. M., Gibson, D. L., Kean, W. F., & Klegeris, A. The biological activity of auranofin: implications for novel treatment of diseases. Inflammopharmacol. 20, 297-306 (2012
13. Roder, C., & Thomson, M. Auranofin: Repurposing an old drug for a golden new age. Drugs in R&D 15, 13-20 (2015
14. Jackson-Rosario, S., et al. Auranofin disrupts selenium metabolism in Clostridium difficile by forming a stable Au-Se adduct. J. Biol. Inorg. Chem. 14, 507-519 (2009
15. Hokai, Y., et al. Auranofin and related heterometallic gold(I)-Thiolates as potent inhibitors of methicillin-resistant Staphylococcus aureus bacterial strains. J. Inorg. Biochem. 138, 81-88 (2014
16. Harbut, M. B., et al. Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis. Proc. Natl. Acad. Sci. USA 112, 4453-4458 (2015
17. Kandi, V., & Kandi, S. Antimicrobial properties of nanomolecules: potential candidates as antibiotics in the era of multi-drug resistance. Epidemiol. Health 37, e2015020 (2015
18. Leid, J. G., et al. In vitro antimicrobial studies of silver carbene complexes: activity of free and nanoparticle carbene formulations against clinical isolates of pathogenic bacteria. J. Antimicrob. Chemother. 67, 138-148 (2012
19. Vert, M., Mauduit, J., & Li, S. Biodegradation of PLA/GA polymers: increasing complexity. Biomaterials 15, 1209-1213 (1994
20. Prokop, A., & Davidson, J. M. Nanovehicular intracellular delivery systems. J. Pharm. Sci. 97, 3518-3590 (2008
21. Danhier, F., et al. PLGA-based nanoparticles: an overview of biomedical applications. J. Control Release 161, 505-522 (2012
22. Mahapatro, A., & Singh, D. Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. J. Nanobiotechnol. 9, 55 (2011
23. Cheng, J., et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 28, 869-876 (2007
24. Meissner, Y., Pellequer, Y., & Lamprecht, A. Nanoparticles in inflammatory bowel disease: particle targeting versus pH-sensitive delivery. Int. J. Pharm. 316, 138-143 (2006
25. Meissner, Y., & Lamprecht, A. Alternative drug delivery approaches for the therapy of inflammatory bowel disease. J. Pharm. Sci. 97, 2878-2891 (2008
26. Panyam, J., & Labhasetwar, V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 55, 329-347 (2003
27. Ladewig, K. Drug delivery in soft tissue engineering. Expert Opin. Drug Deliv. 8, 1175-1188 (2011
28. Lim, H. J., et al. A novel technique for loading of paclitaxel-PLGA nanoparticles onto ePTFE vascular grafts. Biotechnol. Prog. 23, 693-697 (2007
29. Toti, U. S., et al. Targeted delivery of antibiotics to intracellular chlamydial infections using PLGA nanoparticles. Biomaterials 32, 6606-6613 (2011
30. Lecaroz, C., Gamazo, C., & Blanco-Prieto, M. J. Nanocarriers with gentamicin to treat intracellular pathogens. J. Nanosci. Nanotechnol. 6, 3296-3302 (2006
31. Lecaroz, M. C., Blanco-Prieto, M. J., Campanero, M. A., Salman, H., & Gamazo, C. Poly(D, L-lactide-coglycolide) particles containing gentamicin: pharmacokinetics and pharmacodynamics in Brucella melitensis-infected mice. Antimicrob. Agents Chemother. 51, 1185-1190 (2007
32. Imbuluzqueta, E., et al. Novel bioactive hydrophobic gentamicin carriers for the treatment of intracellular bacterial infections. Acta Biomater. 7, 1599-1608 (2011
33. Pillai, R. R., Somayaji, S. N., Rabinovich, M., Hudson, M. C., & Gonsalves, K. E. Nafcillin-loaded PLGA nanoparticles for treatment of osteomyelitis. Biomed. Mater. 3, 034114 (2008
34. Gupta, H., et al. Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery. Nanomedicine: nanotechnology, biology, and medicine 6, 324-333 (2010
35. Díez-Martínez, R., et al. Improving the lethal effect of Cpl-7, a pneumococcal phage lysozyme with broad bactericidal activity, by inverting the net charge of its cell wall-binding module. Antimicrob. Agents Chemother. 57, 5355-5365 (2013
36. Spellberg, B., Bartlett, J., Wunderink, R., & Gilbert, D. N. Novel approaches are needed to develop tomorrow?s antibacterial therapies. Am. J. Respir. Crit. Care Med. 191, 135-140 (2015
37. Gadakh, B., & Aerschot, A. V. Renaissance in antibiotic discovery: some novel approaches for finding drugs to treat bad bugs. Curr. Med. Chem. (in press) (2015
38. Cassetta, M., Marzo, T., Fallani, S., Novelli, A., & Messori, L. Drug repositioning: auranofin as a prospective antimicrobial agent for the treatment of severe staphylococcal infections. Biometals: an international journal on the role of metal ions in biology, biochemistry, and medicine 27, 787-791 (2014
39. Avgoustakis, K., et al. PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J. Control Release. 79, 123-135 (2002
40. Makadia, H. K., & Siegel, S. J. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel) 3, 1377-1397 (2011
41. Anderson, J. M., & Shive, M. S. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev. 28, 5-24 (1997
42. Mohammadi, G., et al. Development of azithromycin-PLGA nanoparticles: physicochemical characterization and antibacterial effect against Salmonella typhi. Colloids Surf. B Biointerfaces. 80, 34-39 (2010
43. Valizadeh, H., et al. Antibacterial activity of clarithromycin loaded PLGA nanoparticles. Die Pharmazie 67, 63-68 (2012
44. Lebeaux, D., Ghigo, J.-M., & Beloin, C. Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics. Microbiol. Mol. Biol. Rev. 78, 510-543 (2014
45. Fonseca, C., Simões, S., & Gaspar, R. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-Tumoral activity. J. Control Release 83, 273-286 (2002
46. Kizu, R., Kaneda, M., Yamauchi, Y., & Miyazaki, M. Determination of auranofin, a chrysotherapy agent, in urine by HPLC with a postcolumn reaction and visible detection. Chem. Pharm. Bull (Tokyo) 41, 1261-1265 (1993
47. Lacks, S., & Hotchkiss, R. D. A study of the genetic material determining an enzyme activity in Pneumococcus. Biochim. Biophys. Acta 39, 508-518 (1960
48. Moscoso, M., García, E., & López, R. Biofilm formation by Streptococcus pneumoniae: role of choline, extracellular DNA, and capsular polysaccharide in microbial accretion. J. Bacteriol. 188, 7785-7795 (2006
49. Hoskins, J., et al. Genome of the bacterium Streptococcus pneumoniae strain R6. J. Bacteriol. 183, 5709-5717 (2001
50. Domenech, M., García, E., & Moscoso, M. In vitro destruction of Streptococcus pneumoniae biofilms with bacterial and phage peptidoglycan hydrolases. Antimicrob. Agents Chemother. 55, 4144-4148 (2011
51. Shen, Y., Köller, T., Kreikemeyer, B., & Nelson, D. C. Rapid degradation of Streptococcus pyogenes biofilms by PlyC, a bacteriophageencoded endolysin. J. Antimicrob. Chemother. 68, 1818-1824 (2013
52. Lanie, J. A., et al. Genome sequence of Avery?s virulent serotype 2 strain D39 of Streptococcus pneumoniae and comparison with that of unencapsulated laboratory strain R6. J. Bacteriol. 189, 38-51 (2007
53. Soriano, F., et al. Breakthrough in penicillin resistance?. Streptococcus pneumoniae isolates with penicillin/cefotaxime MICs of 16 mg/L and their genotypic and geographical relatedness. J. Antimicrob. Chemother. 62, 1234-1240 (2008